People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BioNTech SE | — | Biotechnology | Series D+ | $400.0M | $3.4B | 2020 |
| Bambusa Therapeutics, Inc. | — | Biotechnology | Series C | $67.4M | $375.4M | 2024 |
Helmut Jeggle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Helmut Jeggle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Marett | 2 | 2 |
| Derek DiRocco | 1 | 7 |
| Ryan Richardson | 1 | 2 |
| Michael Motschmann | 1 | 1 |
| Sierk Poetting | 1 | 1 |
| Christoph Huber | 1 | 1 |
| Jens Holstein | 1 | 1 |
| Ozlem Tureci | 1 | 1 |
| Ulrich Wandschneider | 1 | 1 |
| Shanshan Xu | 1 | 1 |
| Ugur Sahin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.